0001477449-24-000109.txt : 20240506
0001477449-24-000109.hdr.sgml : 20240506
20240506160521
ACCESSION NUMBER: 0001477449-24-000109
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240504
FILED AS OF DATE: 20240506
DATE AS OF CHANGE: 20240506
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cave James L.
CENTRAL INDEX KEY: 0002019394
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37477
FILM NUMBER: 24917473
MAIL ADDRESS:
STREET 1: 2 MANHATTANVILLE ROAD
STREET 2: SUITE 203
CITY: PURCHASE
STATE: NY
ZIP: 10577
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Teladoc Health, Inc.
CENTRAL INDEX KEY: 0001477449
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 043705970
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 MANHATTANVILLE ROAD
STREET 2: SUITE 203
CITY: PURCHASE
STATE: NY
ZIP: 10577
BUSINESS PHONE: 2036352002
MAIL ADDRESS:
STREET 1: 2 MANHATTANVILLE ROAD
STREET 2: SUITE 203
CITY: PURCHASE
STATE: NY
ZIP: 10577
FORMER COMPANY:
FORMER CONFORMED NAME: Teladoc, Inc.
DATE OF NAME CHANGE: 20091123
3
1
wk-form3_1715025901.xml
FORM 3
X0206
3
2024-05-04
0
0001477449
Teladoc Health, Inc.
TDOC
0002019394
Cave James L.
C/O TELADOC HEALTH, INC.,
2 MANHATTANVILLE ROAD, SUITE 203
PURCHASE
NY
10577
0
1
0
0
INTERIM CAO
Common Stock
10448
D
Employee Stock Option (right to buy)
151.53
2031-10-31
Common Stock
1493
D
Restricted Stock Units
Common Stock
220
D
Restricted Stock Units
Common Stock
1356
D
Restricted Stock Units
Common Stock
1917
D
Restricted Stock Units
Common Stock
1001
D
Restricted Stock Units
Common Stock
9301
D
Restricted Stock Units
Common Stock
15000
D
The option vested as to 25% of the shares on November 1, 2022. The remainder of the shares vest in 36 substantially equal monthly installments thereafter.
On November 1, 2021, the reporting person was granted 660 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.
Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
On April 1, 2022, the reporting person was granted 4,067 restricted stock units, vesting one-third on March 1, 2023, with the remainder vesting in eight substantially equal quarterly installments thereafter.
On June 1, 2022, the reporting person was granted 4,598 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
On June 1, 2022, the reporting person was granted 4,002 restricted stock units, vesting in four substantially equal semiannual installments beginning on the six-month anniversary of the grant date.
On March 3, 2023, the reporting person was granted 13,951 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
On March 1, 2024, the reporting person was granted 15,000 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Exhibit 24 -- Power of Attorney
/s/ Adam C. Vandervoort, Attorney-in-Fact
2024-05-06
EX-24
2
exhibit24.txt
EX-24
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby
constitutes and appoints Adam C. Vandervoort, Jonathan Dorfman
and Seth Lowinger, or any of them signing singly, and with full
power of substitution and resubstitution, to act as the
undersigned's true and lawful attorney-in-fact to:
1. prepare, execute in the undersigned's name and on the
undersigned's behalf, and submit to the U.S. Securities and
Exchange Commission (the "SEC") a Form ID Application and/or
Passphrase Update Application and/or Request to Convert from
Paper to Electronic Filer, including amendments thereto, and any
other documents necessary or appropriate to obtain and/or
regenerate codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section
16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or any rule or regulation of the SEC;
2. execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or director of Teladoc
Health, Inc., a Delaware corporation (the "Company"), Forms 3, 4
and 5 in accordance with Section 16(a) of the Exchange Act and
the rules thereunder;
3. do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and
execute any such Form 3, 4 or 5, complete and execute any
amendment or amendments thereto, and timely file such form with
the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in
connection with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest of,
or legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's
discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the
exercise of any of the rights and powers herein granted, as fully
to all intents and purposes as the undersigned might or could do
if personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming all
that such attorney-in-fact, or such attorney-in-fact's substitute
or substitutes, shall lawfully do or cause to be done by virtue
of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section
16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4
and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this
Power of Attorney to be executed as of this 10th day of April,
2024.
Signature: /s/ James L. Cave
Print Name: James L. Cave